Maraviroc as GVHD Prophylaxis in Transplant Recipients

NCT02167451 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

31

Enrollment

OTHER

Sponsor class

Stopped slow recruitment and no further drug supply

Conditions

Diagnoses That Require Stem Cell Transplant
Graft Versus Host Disease (GVHD)

Interventions

DRUG: Maraviroc

Sponsor

Children's Hospital Medical Center, Cincinnati